What's Nitya Ray's mailing address?
Nitya's mailing address filed with the SEC is C/O ACTINIUM PHARMACEUTICALS, INC, 275 MADISON AVENUE, 7TH FLOOR, NEW YORK, NY, 10016.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Actinium Pharmaceuticals Inc
Over the last 7 years, insiders at Actinium Pharmaceuticals Inc have traded over $0 worth of Actinium Pharmaceuticals Inc stock and bought 79,730 units worth $38,874 . The most active insiders traders include Anil Kapur, Ajit Shetty oraz Sandesh Seth. On average, Actinium Pharmaceuticals Inc executives and independent directors trade stock every 41 days with the average trade being worth of $22,211. The most recent stock trade was executed by Sandesh Seth on 10 December 2018, trading 10,000 units of ATNM stock currently worth $4,400.
What does Actinium Pharmaceuticals Inc do?
actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o
What does Actinium Pharmaceuticals Inc's logo look like?
Actinium Pharmaceuticals Inc executives and stock owners
Actinium Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Sandesh Seth,
Chairman of the Board, Chief Executive Officer -
Sandesh C. Seth M.B.A., M.S., MBA,
Chairman & CEO -
Mark Berger,
Chief Medical Officer -
Dale Ludwig,
Chief Scientific Officer -
Steve O'Loughlin,
Principal Financial and Accounting Officer -
Steven O'Loughlin BS,
CFO & Corp. Sec. -
C. David Nicholson,
Lead Independent Director -
Richard Steinhart,
Independent Director -
Ajit Shetty,
Independent Director -
Jeffrey Chell,
Independent Director -
Dr. Bernie Cunningham P.M.P., Ph.D.,
Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management -
Dr. Arun Swaminathan Ph.D.,
Chief Bus. & Commercial Officer -
Dr. Avinash Desai M.D.,
Chief Medical Officer -
Dr. Mamata Gokhale,
VP & Global Head of Regulatory Affairs -
Dr. Robert N. Daly M.S., Ph.D.,
VP & Head of Clinical Operations -
Dr. Qing Liang,
VP & Head of Radiation Sciences -
Dr. Bernie Cunningham,
Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management -
Dr. David Gould,
Sr. VP of Corp. Devel. & Corp. Affairs -
Dr. Paul Diamond Esq., Ph.D.,
VP of Patent & Legal Counsel -
Nitya G. Ray,
Executive VP -
Anil Kapur,
Chief Commercial Officer